Pramipexole 0.25 Mg Tablet Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: ER tab: 0.375 mg, 0.75 mg, 1.5 mg, 3 mg, 4.5 mg; IR Tab: 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg
Reference Brands: Mirapex®(US), Sifrol® (EU)
Category: Antipsychotropic Drugs
Pramipexole, a dopamine agonist for Parkinson’s and RLS, is available as 0.125–4.5 mg tablets. Brands include Mirapex® and Sifrol®. Pharma B2B platforms provide bulk access to GMP-certified Pramipexole with global regulatory compliance and consistent supply for hospitals, neurology practices, and pharmaceutical distributors.
Product Description:
Pramipexole is a dopamine agonist used in the treatment of Parkinson’s disease and restless legs syndrome (RLS). It is available in both immediate- and extended-release oral tablet forms with strengths ranging from 0.125 mg to 4.5 mg. Marketed under brands like Mirapex® in the US and Sifrol® in the EU, Pramipexole helps improve motor function and reduce symptoms in neurological disorders. Pharma B2B suppliers offer bulk procurement of Pramipexole from GMP-certified manufacturers, ensuring quality, regulatory compliance, and efficient global supply. Ideal for pharmacies, distributors, and hospital procurement across neurology and chronic care specialties.
Pramipexole 0.25 Mg Tablet — third party manufacturing & bulk supply
Pramipexole 0.25 Mg Tablet is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:
What to include when you enquire
- Destination market — determines which manufacturers hold the right site-level approvals
- First order quantity and estimated annual volume
- Whether you need a registration dossier or the product is already registered
- Packaging, labelling and language requirements
- Incoterms and required shelf life
Manufacturers of Pramipexole 0.25 Mg Tablet listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding. Narcotic drugs and controlled substances are supplied strictly against valid import and export permits issued by the competent authorities.
Request a quote for Pramipexole 0.25 Mg Tablet →The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Pramipexole is used for the treatment of Parkinson’s disease and restless legs syndrome (RLS). It helps improve motor symptoms such as stiffness, tremor, and impaired movement by stimulating dopamine receptors in the brain.
Pramipexole is a synthetic dopamine agonist. The complete generic name is pramipexole dihydrochloride monohydrate, which is chemically synthesized and not derived from any biological source.
Pramipexole is marketed under trade names such as Mirapex and Sifrol in different global markets.
The original branded versions of pramipexole were developed by Boehringer Ingelheim. Today, it is manufactured by multiple generic pharmaceutical companies worldwide.
The generic name of Pramipexole is pramipexole dihydrochloride monohydrate.
The commonly known brand names of Pramipexole include Mirapex and Sifrol.
Pramipexole is manufactured in various countries including India, the USA, and several European countries by approved pharmaceutical manufacturers.
Related Products
Lithium Carbonate
Strength:
150 mg, 300 mg, 600 mg
Form: Tablets
Reference Brands: Lithobid (USA/LATAM), Priadel (EU)
View Details
Phenobarbital Sodium
Strength:
65 mg/mL, 130 mg/mL.
Form: Injection
Reference Brands: Generic formulations marketed under different names
View DetailsQuick Response Guaranteed | Verified Suppliers
